Clinical trial · Observational
Liver Function Investigation With SPECT
Liver Function Investigation With Single Photon Emission Computed Tomography After Radiotherapy
NCT02967848CI-TRIAL-00102583LiverINSPECTactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase 1 pilot study to assess feasibility and utility of 99mTc-mebrofenin hepatobiliary scintigraphy for measurement of functional liver change due to radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer, Adult | Malignant Liver Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 99mTc-mebrofenin hepatobiliary scintigraphy (HBS) | Other | — | UNRESOLVED |
| Indocyanine Green | Other | — | UNRESOLVED |
| Liver Elasticity | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with Cancers in Liver
- description
- Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
- interventionNames
- Other: 99mTc-mebrofenin hepatobiliary scintigraphy (HBS)
- Other: Indocyanine Green
- Other: Liver Elasticity
Primary outcomes (1)
- measure
- Change in global and local liver function
- timeFrame
- 3 years
- description
- 99mTC-mebrofenin hepatobiliary scintigraphy images after stereotactic ablative body radiotherapy to cancers of the liver. This will be reported as a change in function as a function of delivered radiotherapy dose.
Secondary outcomes (3)
- measure
- Correlation between 99mTC mebrofenin HBS and various measures of global function
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 or older * Has provided written Informed Consent for participation in this trial and is willing to comply with the study * Patients undergoing external beam radiotherapy at Northern Sydney Cancer Centre * Histologically proven hepatocellular carcinoma or oligometastatic liver metastases (3 or less). Histological diagnosis will be obtained if clinically indicated. * ECOG performance status 0-2 Exclusion Criteria: * Previous high-dose radiotherapy to the liver * Previous SIRT * Women who are pregnant or lactating * Unwilling or unable to give informed consent * No venous access * Inability to lie supine and still for 30 minutes * History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy (excluded from ICG testing only) * Pacemaker (excluded from Fibroscan elasticity test only)
References
Publications (0)
Data not yet available
No reference posted for this study.